PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data
- DOI
- 10.3389/fimmu.2026.1958007
- Published
- 2026-10-06
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1958007,
title = {PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data},
author = {Bing Guan and Yawen Chen and Rong Zhou and Sijia Zhang and Lulu Li and Ping He},
year = {2026},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2026.1958007},
url = {https://doi.org/10.3389/fimmu.2026.1958007}
}RIS
TY - JOUR TI - PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data AU - Bing Guan AU - Yawen Chen AU - Rong Zhou AU - Sijia Zhang AU - Lulu Li AU - Ping He PY - 2026 JO - Frontiers in Immunology DO - 10.3389/fimmu.2026.1958007 UR - https://doi.org/10.3389/fimmu.2026.1958007 ER -
APA
Guan, B., Chen, Y., Zhou, R., Zhang, S., Li, L., & He, P. (2026). PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1958007
Source records
- crossref · retrieved 2026-11-10T11:32:28.582Z